Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 9/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | GCG | P01275 | 1/20 | 0.40 |
| ▸ | RHOC | P08134 | 1/20 | 0.40 |
| ▸ | RHOA | P61586 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | STAT1 | P42224 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111640 | 0.93 | CNR1 (0.44) | CNR1CNR2GCGRMALT1PPARD | |
| SCHEMBL3113188 | 0.89 | PPARD (0.44) | CNR1CNR2GCGRMALT1PPARD | |
| SCHEMBL3110196 | 0.87 | DPP4 (0.48) | CNR1CNR2GCGRMALT1PPARD | |
| SCHEMBL3111104 | 0.85 | DDR1 (0.44) | CNR1CNR2GCGRMALT1PPARD | |
| SCHEMBL3107295 | 0.84 | CNR1 (0.47) | CNR1CNR2GCGRMALT1PPARD | |
| SCHEMBL3106128 | 0.84 | CNR1 (0.40) | CNR1GCGRGCGRHOCRHOA | |
| SCHEMBL3660685 | 0.83 | PPARD (0.41) | CNR1CNR2GCGRMALT1PPARD | |
| SCHEMBL3100296 | 0.82 | DDR1 (0.45) | CNR1CNR2GCGRMALT1PPARD | |
| SCHEMBL3113355 | 0.81 | PPARD (0.47) | CNR1CNR2MALT1PPARDRHOC | |
| SCHEMBL3113330 | 0.80 | DDR1 (0.41) | CNR1CNR2GCGRMALT1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362045-B2 | 5,6-diaryl pyridines substituted in the 2- and 3-position, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-29 | — | — | US | claimed |
| US-20100256202-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-10-07 | — | — | US | claimed |
| EP-2209768-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-07-28 | — | — | EP | claimed |
| WO-2009087285-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-07-16 | — | — | WO | claimed |
| US-8362045-B2 | 5,6-diaryl pyridines substituted in the 2- and 3-position, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-29 | — | — | US | disclosed |
| US-20100256202-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-10-07 | — | — | US | disclosed |
| EP-2209768-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-07-28 | — | — | EP | disclosed |
| US-7682603-B2 | Polymersomes incorporating highly emissive probes | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-03-23 | — | — | US | disclosed |
| WO-2009087285-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-07-16 | — | — | WO | disclosed |
| WO-2007106900-A2 | QUANTITATIVE MOLECULAR PROBES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2007-09-20 | — | — | WO | disclosed |
| EP-1659938-A2 | POLYMERSOMES INCORPORATING HIGHLY EMISSIVE PROBES | The Trustees of The University of Pennsylvania (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016259-A2 | POLYMERSOMES INCORPORATING HIGHLY EMISSIVE PROBES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050019265-A1 | Polymersomes incorporating highly emissive probes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256202-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | ALK, ROS1, CYP11B2 | CNR1 11/4885CNR2 4/4885GCGR 765/4885 |
| US-20050019265-A1 | Polymersomes incorporating highly emissive probes | PML, PAICS, MKI67 | CNR1 1513/4885CNR2 1262/4885GCGR 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.